X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs GLENMARK PHARMA - Comparison Results

LUPIN    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN GLENMARK PHARMA LUPIN/
GLENMARK PHARMA
 
P/E (TTM) x 40.6 16.7 243.5% View Chart
P/BV x 2.5 3.0 84.2% View Chart
Dividend Yield % 0.7 0.4 187.8%  

Financials

 LUPIN   GLENMARK PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-18
GLENMARK PHARMA
Mar-18
LUPIN/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,465930 157.5%   
Low Rs727517 140.5%   
Sales per share (Unadj.) Rs349.6322.6 108.4%  
Earnings per share (Unadj.) Rs5.628.5 19.5%  
Cash flow per share (Unadj.) Rs29.639.2 75.5%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.50.3 165.1%  
Book value per share (Unadj.) Rs300.3183.0 164.1%  
Shares outstanding (eoy) m452.08282.17 160.2%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.12.2 139.8%   
Avg P/E ratio x197.225.4 776.3%  
P/CF ratio (eoy) x37.118.5 200.7%  
Price / Book Value ratio x3.64.0 92.3%  
Dividend payout %90.07.0 1,281.5%   
Avg Mkt Cap Rs m495,502204,206 242.6%   
No. of employees `00017.013.7 124.2%   
Total wages/salary Rs m28,64718,718 153.0%   
Avg. sales/employee Rs Th9,273.66,636.8 139.7%   
Avg. wages/employee Rs Th1,681.01,364.7 123.2%   
Avg. net profit/employee Rs Th147.4586.1 25.2%   
INCOME DATA
Net Sales Rs m158,04291,031 173.6%  
Other income Rs m1,504914 164.5%   
Total revenues Rs m159,54591,945 173.5%   
Gross profit Rs m31,47516,154 194.8%  
Depreciation Rs m10,8593,019 359.7%   
Interest Rs m2,0442,856 71.6%   
Profit before tax Rs m20,07611,193 179.4%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,6440-   
Tax Rs m2,8853,155 91.4%   
Profit after tax Rs m2,5138,039 31.3%  
Gross profit margin %19.917.7 112.2%  
Effective tax rate %14.428.2 51.0%   
Net profit margin %1.68.8 18.0%  
BALANCE SHEET DATA
Current assets Rs m122,09569,887 174.7%   
Current liabilities Rs m50,95632,879 155.0%   
Net working cap to sales %45.040.7 110.7%  
Current ratio x2.42.1 112.7%  
Inventory Days Days8581 103.9%  
Debtors Days Days12093 128.3%  
Net fixed assets Rs m129,87628,892 449.5%   
Share capital Rs m904282 320.4%   
"Free" reserves Rs m134,86651,353 262.6%   
Net worth Rs m135,77151,635 262.9%   
Long term debt Rs m64,24541,418 155.1%   
Total assets Rs m263,054125,954 208.8%  
Interest coverage x10.84.9 220.0%   
Debt to equity ratio x0.50.8 59.0%  
Sales to assets ratio x0.60.7 83.1%   
Return on assets %1.78.6 20.0%  
Return on equity %1.915.6 11.9%  
Return on capital %3.715.1 24.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,14136,317 146.3%   
Fx outflow Rs m19,3359,720 198.9%   
Net fx Rs m33,80726,598 127.1%   
CASH FLOW
From Operations Rs m17,51216,481 106.3%  
From Investments Rs m-14,073-10,133 138.9%  
From Financial Activity Rs m-14,921-4,685 318.5%  
Net Cashflow Rs m-11,4821,770 -648.7%  

Share Holding

Indian Promoters % 46.6 48.3 96.5%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 6.9 163.8%  
FIIs % 31.9 34.4 92.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 10.5 96.2%  
Shareholders   98,259 56,727 173.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare LUPIN With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Dip After Record Rally; Sensex Ends 298 Points Lower(Closing)

It was a volatile day for Indian share markets today. The BSE Sensex and NSE Nifty opened at record high and went on to touch 40,000 and 12,000.

Related Views on News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 23, 2019 (Close)

TRACK LUPIN

LUPIN - FRESENIUS KABI ONCO. COMPARISON

COMPARE LUPIN WITH

MARKET STATS